Research programme: p38 MAP kinase inhibitors - ArQule

Drug Profile

Research programme: p38 MAP kinase inhibitors - ArQule

Alternative Names: ARQ-101

Latest Information Update: 26 May 2010

Price : $50

At a glance

  • Originator ArQule; SignalGene [CEASED]
  • Class Oxazoles; Thiazoles
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 23 Sep 2005 Compounds arising from this programme are available for out-licensing (http://www.arqule.com)
  • 23 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th ACS-2005) have been added to the Rheumatic Disease pharmacodynamics section
  • 01 Sep 2005 ARQ 101 from this programme is still in active development - BIO-2005 Annual International Convention (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top